The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
108814355 10881435 5 F 201502 20160826 20150303 20160906 EXP PHHY2010CA19119 NOVARTIS 52.62 YR M Y 0.00000 20160906 MD CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
108814355 10881435 1 PS SANDOSTATIN OCTREOTIDE ACETATE 1 Subcutaneous UNK U 19667
108814355 10881435 2 SS SANDOSTATIN LAR DEPOT OCTREOTIDE ACETATE 1 Intramuscular 40 MG, QMO (EVERY 4 WEEKS) U 0 40 MG SUSPENSION /month
108814355 10881435 3 SS SANDOSTATIN LAR DEPOT OCTREOTIDE ACETATE 1 Intramuscular 40 MG, QMO (EVERY 4 WEEKS) U 0 40 MG SUSPENSION /month
108814355 10881435 4 SS SANDOSTATIN LAR DEPOT OCTREOTIDE ACETATE 1 Intramuscular 20 MG, QMO U 0 20 MG SUSPENSION /month
108814355 10881435 5 SS SANDOSTATIN LAR DEPOT OCTREOTIDE ACETATE 1 Intramuscular 40 MG, QMO (EVERY 4 WEEKS) U 0 40 MG SUSPENSION /month
108814355 10881435 6 SS SANDOSTATIN LAR DEPOT OCTREOTIDE ACETATE 1 Intramuscular 40 MG, QMO (EVERY 4 WEEKS) U 0 40 MG SUSPENSION /month
108814355 10881435 7 SS AFINITOR EVEROLIMUS 1 Oral 10 MG, QD 0 10 MG QD
108814355 10881435 8 C DIABINESE CHLORPROPAMIDE 1 Unknown 250 MG, QD U 0 250 MG QD
108814355 10881435 9 C COVERSYL /FRA/ PERINDOPRIL 1 Unknown 04 MG, UNK U 0 4 MG
108814355 10881435 10 C SUTENT SUNITINIB MALATE 1 Unknown 37.5 MG, QD U 0 37.5 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
108814355 10881435 1 Pancreatic neuroendocrine tumour metastatic
108814355 10881435 2 Pancreatic neuroendocrine tumour metastatic
108814355 10881435 7 Pancreatic neuroendocrine tumour metastatic
108814355 10881435 8 Product used for unknown indication
108814355 10881435 9 Product used for unknown indication
108814355 10881435 10 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
108814355 10881435 HO
108814355 10881435 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
108814355 10881435 Bacterial infection
108814355 10881435 Blood pressure decreased
108814355 10881435 Blood pressure increased
108814355 10881435 Body temperature decreased
108814355 10881435 Dental caries
108814355 10881435 Duodenal obstruction
108814355 10881435 Fatigue
108814355 10881435 Gingivitis
108814355 10881435 Headache
108814355 10881435 Hypersomnia
108814355 10881435 Metastases to liver
108814355 10881435 Pancreatic carcinoma
108814355 10881435 Tooth infection
108814355 10881435 Vision blurred

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
108814355 10881435 1 20100301 0
108814355 10881435 2 20100319 0
108814355 10881435 7 20110324 20120216 0
108814355 10881435 10 201608 0